Ali BA, Salman M, Ghanem KM, et al. - Given a dramatic improvement in outcomes in pediatric osteosarcoma over the past few decades, with overall survival rates of 70% and 30% for patients with localized and metastatic disease, respectively, researchers retrospectively reviewed data of 38 patients treated between 2001 and 2012 at a single institution in Lebanon, for clinical characteristics and outcomes. A uniform three-drug chemotherapy regimen consisting of cisplatin, doxorubicin, and methotrexate was provided to all patients and addition of ifosfamide and etoposide was done in case of metastatic disease and/or poor degree of tumor necrosis (< 90%). In a multidisciplinary cancer center in Lebanon, treatment of pediatric osteosarcoma led to survival similar to that in developed countries. The worse outcome was observed in correlation with a delay in local control. Poor degree of necrosis at the time of local control was the only statistically significant inferior outcome predictor.